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in Saccharomyces cerevisiae strains evolved 
for enhanced protein secretion
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Abstract 
Monoclonal antibodies, antibody fragments and fusion proteins derived thereof have revolutionized the practice 
of medicine. Major challenges faced by the biopharmaceutical industry are however high production costs, long 
processing times and low productivities associated with their production in mammalian cell lines. The yeast Saccharo-
myces cerevisiae, a well-characterized eukaryotic cell factory possessing the capacity of post translational modifications, 
has been industrially exploited as a secretion host for production of a range of products, including pharmaceuticals. 
However, due to the incompatible surface glycosylation, few antibody molecules have been functionally expressed in 
S. cerevisiae. Here, three non-glycosylated antibody fragments from human and the Camelidae family were chosen for 
expression in a S. cerevisiae strain (HA) previously evolved for high α-amylase secretion. These included the Fab frag-
ment Ranibizumab (Ran), the scFv peptide Pexelizumab (Pex), and a nanobody consisting of a single V-type domain 
(Nan). Both secretion and biological activities of the antibody fragments were confirmed. In addition, the secretion 
level of each protein was compared in the wild type (LA) and two evolved strains (HA and MA) with different secretory 
capacities. We found that the secretion of Ran and Nan was positively correlated with the strains’ secretory capacity, 
while Pex was most efficiently secreted in the parental strain. To investigate the mechanisms for different secretion 
abilities in these selected yeast strains for the different antibody fragments, RNA-seq analysis was performed. The 
results showed that several bioprocesses were significantly enriched for differentially expressed genes when compar-
ing the enriched terms between HA.Nan vs. LA.Nan and HA.Pex vs. LA.Pex, including amino acid metabolism, protein 
synthesis, cell cycle and others, which indicates that there are unique physiological needs for each antibody fragment 
secretion.
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Background
Production of monoclonal antibodies (mAbs) has over 
the last three decades evolved into an extremely impor-
tant branch of the biopharmaceutical industry. The 
applications of mAbs are rapidly expanding, includ-
ing protein-based in  vitro diagnostic tests, high-affinity 
protein purification methods, and the treatment of a wide 
array of major human diseases such as cancer, inflamma-
tion, autoimmune disorders, as well as cardiovascular 
and infectious diseases [1–3]. More recently, interest has 
shifted towards the study of minimal antibody-binding 
fragments, owing to their prominent advantages, such as 
high specificity, higher affinity and tissue penetrability, 
superior stability and solubility, reduced immunogenicity 
as well as easier and less expensive large-scale production 
[1, 4]. Three classes of antibody fragments, including Fab 
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fragment), and the single V-type domain, represent suc-
cessive waves of antibody fragment technologies [5, 6]. 
However, isolation of intact and biologically specific anti-
body fragments by proteolysis such as papain and pep-
sin digestion is challenging [5, 7]. On the other hand, 
recombinant DNA technology opened the possibility of 
expressing antibody fragment genes in heterologous host 
organisms that are easy to manipulate and cultivate.
  Mammalian cells and microorganisms, such as 
the bacterium Escherichia coli and yeasts, have been 
exploited as the main cell factories, which collectively 
account for the production of 89% of approved biophar-
maceuticals [8]. Modified Chinese hamster ovary (CHO) 
cells produced up to 100  mg/L of VhHs in shake flasks 
[9]. The use of mammalian cells in bioprocessing, how-
ever, has some drawbacks, such as low product yield and 
growth rate, a high risk of viral contamination and the 
requirement for expensive growth medium. The use of 
microbial host organisms has therefore drawn increasing 
attention [8, 10]. Indeed, there have been several reports 
on engineering E. coli for the production of antibody 
fragments [7, 11, 12]. For example, through engineering 
of E. coli, several grams per liter of the recombinant anti-
body fragments scFv and Fab can be achieved in ferment-
ers [13]. Compared with the bacterial expression systems, 
yeasts prove to be more desirable hosts for industrial-
scale production of recombinant proteins due to their 
ability to perform post-translational modifications. Fur-
thermore, their high robustness and tolerance towards 
harsh fermentation conditions, which are key factors in 
bioprocessing and scale-up, are additional advantages. 
Two anti-MUC1 VhHs were successfully expressed in 
Pichia pastoris for the first time, and titers in the range 
of 10–15 mg/L were obtained after a series of optimiza-
tions [14]. A major limitation for using S. cerevisiae as the 
antibody expression host is its native hyper-mannose gly-
cosylation, which is highly antigenic in mammals [10, 15]. 
However, the absence of glycosylation sites on many anti-
body fragments circumvents this problem, further adding 
to the good prospect for yeast as a platform for produc-
tion of this group of pharmaceuticals.
S. cerevisiae is a preferred microbial cell factory for 
production of a variety of biopharmaceuticals due to its 
ability to secrete proteins, which facilitates their sub-
sequent isolation, purification, and avoids the possible 
toxic intracellular build-up of foreign protein, and there-
fore significantly reduces the production costs [16, 17]. 
Although the secretory pathway in yeast is complex, it is 
still an attractive engineering target to improve the cell´s 
capacity to process the proteins of interest. Much work 
has been focused on overcoming the various limitations, 
optimizing the secretory processes [18, 19] and thus 
enhancing protein production. For instance, different 
antibodies and antibody fragments were successfully 
expressed in yeast [20–23], and engineering protein 
folding increased the antibody yields up to 10-fold [24]. 
Similar strategies were also employed to produce other 
proteins [21, 25] such as engineering vesicle traffick-
ing, which improved the α-amylase titer up to 15-fold 
in glucose-limited fed batch cultivations [26]. Despite 
the success of targeted engineering, this has often been 
beneficial only for the production of the protein of inter-
est, but not heterologous proteins in general [27]. Our 
laboratory previously isolated a group of yeast mutant 
strains with significantly elevated α-amylase produc-
tion through random mutagenesis and microfluidic 
screening [28]. Among these strains, the best producer 
B184 was the descendant of MH34, which was in turn 
derived from AAC (the parental strain), and the pro-
duction capacity gradually increased with each round 
of mutagenesis (Fig.  1) [28]. Furthermore, these mutant 
strains also showed increased secretion capacity for the 
other heterologous proteins, Rhizopus oryzae glucan 
1,4-α-glucosidase [28] and Trichoderma reesei endo-
1,4-beta-xylanase II [29]. Regardless of the progress in 
understanding protein secretion mechanisms, it is still 
not known whether the improved secretory capacity of 
these strains extends to heterologous proteins of phar-
maceutical relevance, such as antibodies and antibody 
fragments.
Here, we characterized the expression of three rep-
resentative antibody fragment drugs, including Ran 
(Ranibizumab, Fab fragment), Pex (Pexelizumab, scFv 
peptide) and Nan (Nanobody, single V-type domain) 
(Table 1), in a previously constructed high amylase pro-
ductive strain HA (derived from B184). Subsequently, we 
demonstrated the biological activities of these proteins 
through ELISA and pull-down assay. Furthermore, we 
compared the production profiles of antibody fragments 
in different host variants LA (derived from AAC), MA 
(derived from MH34) and HA. Ultimately, RNA-seq was 
performed to explore the underlying mechanism upon 
observed differences in secretion capacities.
Results
Secretion of antibody fragments by S. cerevisiae
In a previous study, B184 showed the highest α-amylase 
secretion level among all isolated mutant strains [28]. 
Therefore, we first expressed the antibody fragments 
in the HA host strain, i.e. B184 after the loss of the 
α-amylase expression plasmid. To maintain high plas-
mid stability and generate higher cell copy numbers, 
we used the CPOTud plasmid as the expression vector, 
in which the equivatent POT1 gene from the glycolytic 
pathway of Schizosaccharomyces pombe was used as a 
selective marker to complement the lack of the TPI1 
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gene in the host strain [33] (Fig. 2a). To direct heterolo-
gous proteins through the secretory pathway, the secre-
tory signal peptide derived from the α-factor was added 
to the N-terminus of the antibody fragments. To ensure 
high translation initiation efficiency of the target pro-
teins, a Kozak sequence (aacaaa) was inserted before 
the start codon of the gene [34]. In addition, a spacer 
sequence (EEGEPK) was included at the C-terminus 
of the leader peptide to increase the cleavage efficien-
cies of the pro-leader [35]. The resulting plasmids that 
encoded Nan (single V-type domain), Pex (scFv), and 
Ran (Fab) were introduced into HA, obtaining strains 
HA.Nan, HA.Pex and HA.Ran, respectively.
To confirm the expression and secretion of Nan and 
Pex proteins, we first performed an SDS-PAGE analysis 
(Fig.  2b). While showing a weak band for the Nan pro-
tein, no Pex was detected when the supernatant was not 
concentrated. After concentrating the supernatants of 
HA.Nan and HA.Pex 25-fold and 270-fold, the clear pro-
tein bands of 17 kDa and 31 kDa corresponding to Nan 
and Pex, respectively, were detected. Subsequently, we 
performed western blot analysis using an anti-6x-His-
tag monoclonal antibody under reducing conditions. As 
shown in Fig. 2c and d (raw blots in Additional file 1: Fig. 
S1a and S1b), both detected protein signals were in agree-
ment with the expected sizes. Interestingly, an additional 
Fig. 1 Schematic workflow for exploring the secretion capacity for antibody fragments of different mutant strains. a Three yeast strains evolved 
for significantly improved protein secretion based on α-amylase production. AAC, parental strain; MH34, intermediate strain; B184, highest level 
α-amylase secreting strain. b Strains after elimination of α-amylase plasmid from the mutant strains. LA, derived from AAC; MA, derived from MH34; 
HA, derived from B184. c Three new plasmids generated by inserting the three different antibody fragments genes (Nan, Pex and Ran) into the 
CPOTud vector, respectively. d Strains harboring plasmids for expression of Nan, Pex and Ran, respectively. Nine strains (LA.Nan, LA.Pex, LA.Ran, 
MA.Nan, MA.Pex, MA.Ran, HA.Nan, HA.Pex, and HA.Ran) were thus generated. e A series of functional analysis experiments was performed after 
shake flask fermentations of the strains harboring the different expression plasmids. f RNA-seq data were collected and integrated, resulting in an 
overall biological interpretation of antibody fragment production
Table 1 Therapeutic antibody fragments used in this study
a VH, variable domain of heavy chain;  VL, variable domain of heavy chain;  CH1, the first constant domain of heavy chain;  CL, constant domain of light chain
b The sequence of polypeptide linker is GGGGSGGGGSGGGGS





Nanobody  (Nan, Camelid) VhH Single monomeric  VH 17 kDa 5.92 2 Lysozyme Rheumatoid arthritis and 
Crohn´s disease [30]
Pexelizumab  (Pex, Humanized) scFv VH and  VL connected 
by a polypeptide 
 linkerb
31 kDa 8.62 Uncertain Complement C5 Coronary artery bypass and 
Angioplasty [31]
Ranibizumab  (Ran, Humanized) Fab VH,  VL,  CH1 and  CL 51 kDa 6.99 5 VEGF-A Macular degeneration [32]
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protein band of ca. 14  kDa potentially stemming from 
partial degradation was found for the HA.Pex strain 
(Fig. 2d, Additional file 1: Fig. S1b), but this band was not 
detected in the control strain HA.CPOTud carrying the 
empty CPOTud vector. Previous studies reported that 
Kex2 endoprotease, specific for dibasic Lys-Arg sites, 
cleaves the leader-fusion protein in the late secretory 
pathway [35, 36]. As there is a Lys-Arg site present in the 
Pex protein sequence  (K129R130), we hypothesized that 
the small band could be caused by Kex2 cleavage. To test 
this hypothesis, an R130K substitution was introduced 
into Pex, generating the strain HA.Pex (R130K). How-
ever, the continued appearance of this smaller fragment 
ruled out this possibility (Additional file  1: Fig. S2). We 
Fig. 2 The expression of antibody fragments in S. cerevisiae. a Schematic of CPOTud-based vector for expression of antibody fragments in S. 
cerevisiae. VhH/VH, variable heavy chain;  VL, variable light chain;  CH1, the first constant domain of the heavy chain;  CL, constant light chain; FLAG, 
FLAG-tag at the C-terminus of genes; his6, 6xHis-tag at the C terminus of genes; α-pre and α-pro, the components of α-factor leader, which is 
a native secretion leader; 2A, 2A peptide; Yap3-TA57, a synthetic secretion leader; POT1, selective marker from Schizosaccharomyces pombe to 
complement the lack of the TPI1 gene in the host; 2 μm, 2 micron origin. b SDS-PAGE gel for the detection of antibody fragments in the HA host 
strain. 1, HA.CPOTud; 2, HA.Nan; 3, HA.Ran; 4, HA.Ran (non-reducing); 5, HA.Pex; M, protein ladder; 6, HA.CPOTud; 7, HA.Nan; 8, HA.CPOTud; 9, HA.Ran; 
10, HA.CPOTud (non-reducing condition); 11, HA.Ran (non-reducing condition); 12, HA.CPOTud; 13, HA.Pex; 1–5, non-concentrated supernatant; 
6–13, supernatants concentrated 25-, 50- or 270-fold using 10 K MW Pierce Concentrator PES. Arrows indicate expected proteins. MW, protein 
ladder. Western blots of cell supernatant from recombinant strains based on the HA host strain to detected proteins Nan (c), Pex (d) and Ran (e). 
Secreted antibody fragments were obtained after cultivation in SD-2xSCAA without BSA for 72 h. Nan, Pex and Ran-H were detected using an 
anti-6x-His-tag monoclonal antibody. Ran-L was detected using an anti-FLAG-tag monoclonal antibody. Nan and Pex were analyzed under reducing 
conditions. Ran was analyzed under reducing (R, left lane in each panel) and nonreducing (NR, right lane of each panel) conditions. The original 
images of the western blots are shown in Additional file 1: Fig. S1
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speculated that the additional band could result from a 
potential peptide bond hydrolysis that happens close to 
the linker sequence. The calculated molecular size might 
support this assumption.
Fab consists of two separate proteins including heavy 
chain and light chain. Therefore, the coordinated expres-
sion of these two chains is very important for the forma-
tion of the intact Fab. There are different possibilities to 
achieve this coordinated expression, e.g. the introduc-
tion of a 2A peptide sequence [37, 38]. Due to the poly-
cistronic nature, small size and high “cleavage” efficiency, 
2A peptides have received increased interest. 2A-pep-
tide linked genes are translated from a single mRNA 
and “self-cleaved” through ribosomal skipping, which 
occurs co-translationally resulting in equal amounts 
of the co-expressed proteins [39]. In a previous study, 
the 2A peptide from Thosea asigna virus resulted in the 
highest cleavage efficiency and the highest expression 
level of three biosimilar IgG1 antibodies in CHO cells 
[40]. Therefore, it was considered interesting to evalu-
ate expression of the third antibody fragment using this 
2A self-processing peptide. We introduced the 2A pep-
tide coding sequence into the Ran gene, an additional KR 
sequence and a GSG linker in front of the 2A peptide, an 
alpha factor leader and synthetic leader Yap3-TA57 at 
the N terminus of heavy chain (Ran-H) and light chain 
(Ran-L) and a 6xHis-tag and FLAG-tag at the C termi-
nus of Ran-H and Ran-L, respectively. Subsequently, we 
characterized the expression of Ran-H and Ran-L using 
the 2A-containing construct. After concentrating the 
supernatant of HA.Ran 50-fold, we observed a band 
between 20  kDa and 30  kDa compared to concentrated 
HA.CPOTud under reducing conditions on the SDS-
PAGE gel. But the similar molecular weights of Ran-H 
(26 kDa) and Ran-L (25 kDa) prevented us from clearly 
distinguishing these two bands (Fig.  2b). We could not 
observe the full-length Ran (51 kDa) under non-reducing 
conditions owing to the low expression level. The migra-
tion of the translation products was recorded by western 
blot under both reducing and non-reducing conditions 
using an anti-6x-His-tag monoclonal antibody and an 
anti-FLAG-tag monoclonal antibody, which recognized 
Ran-H and Ran-L, respectively. As expected, under 
reducing conditions, two protein bands were detected, 
corresponding to the molecular weights of Ran-H and 
Ran-L, respectively (Fig.  2e, Additional file  1: Fig. S1c). 
This result indicated that “self-cleavage” of the 2A pep-
tide occurred during protein translation. Western blot 
analysis under non-reducing condition revealed a band 
of approximately 51  kDa, which is the expected size 
of a full-length Ran composed of both heavy chain and 
light chain. However, one additional protein band was 
detected at a position correlating to the size of heavy 
chain and light chain, respectively, which could be attrib-
uted to incomplete assembly of the heavy and light 
chains.
To avoid potential interference with the target proteins, 
we did not supplement the SD-2xSCAA medium with 
bovine serum albumin (BSA) although a previous study 
demonstrated that the addition of BSA in the fermenta-
tion medium could significantly reduce heterologous 
protein degradation by extracellular proteases in S. cer-
evisiae [41]. After confirming the expression and secre-
tion of antibody fragments, we tested the influence of 
BSA on target protein production through culturing the 
strain LA.Nan in SD-2xSCAA medium and SD-2xSCAA 
medium without BSA. In accordance with the previ-
ous report, the strain growing in SD-2xSCAA medium 
resulted in a higher Nan production at different time-
points (Additional file  1: Fig. S3). This result indicated 
that the presence of BSA could to some extent protect 
the protein product from being degraded. Therefore, 
we added BSA to the medium throughout the following 
experiments to avoid potential protein degradation.
Taken together, all three strains produced protein 
bands of the expected molecular sizes, confirming that 
all selected antibody fragments could be expressed and 
secreted as soluble proteins in S. cerevisiae.
In vitro antibody activity assay
After the confirmation of protein expression and secre-
tion of the selected antibody fragments, we proceeded 
to measure their biological activities. For this, an ELISA 
binding assay protocol was implemented to measure the 
protein-protein interaction between antibody fragments 
and their respective immobilized antigens. Figure  3a 
schematically illustrates the principle.
Since ELISA-based assays are highly specific and sensi-
tive, we routinely purified the proteins from the culture 
supernatant using cobalt-based immunoprecipitation in 
order to avoid any interference by protein impurities in 
the medium. Subsequently, the purified proteins were 
serially diluted and tested by ELISA (Additional file 1: Fig. 
S4). The results showed an increase of absorbance values 
 (OD450) in line with the increased concentration of pro-
teins (Nan, Pex and Ran), while the control HA.CPOTud 
strain did not result in any absorbance at this wavelength, 
which indicated that the three heterologous proteins 
could specifically bind to their antigens.
In previous reports, the harvested culture supernatant 
was directly subjected to ELISA analysis [40, 42–44]. 
To evaluate if this was feasible here, we performed the 
respective experiment and proved that no biological 
activity was observed in the supernatant from control 
strain HA.CPOTud, which harbored the empty plasmid, 
indicating that impurities in the cultivation medium did 
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not result in an unspecific reaction of the ELISA assay. 
Therefore, to simplify the analysis process and minimize 
protein loss, we omitted the purification process and 
instead directly collected the supernatant to measure 
binding activity. Consistent with above ELISA experi-
ments using purified proteins (Additional file  1: Fig. 
S4), expression of three antibody fragments resulted in 
a marked increase of absorbance values  (OD450) reveal-
ing the binding activity with increasing concentration of 
supernatant (Fig. 3b–d).
To obtain additional evidence about its biological 
specificity, we selected antibody fragment Nan (with 
C-6xHis-tag) as an example and further demonstrated 
its binding to the corresponding target protein lysozyme 
from chicken egg white (Lyz, with C-FLAG-tag) using 
a pull-down assay. Additional file  1: Fig. S5a illustrates 
the reaction process. Western blot analysis using anti-
FLAG-tag monoclonal antibody resulted in detection of 
a Lyz band at the expected size (15 kDa) in the superna-
tant, which confirmed that the protein Lyz was secreted 
(Additional file  1: Fig. S5b). The interaction was dem-
onstrated by the appearance of two protein bands in a 
reducing SDS-PAGE gel at molecular weights of approx-
imately 17  kDa and 15  kDa (Additional file  1: Fig. S5c), 
corresponding to Nan and Lyz, respectively. The binding 
specificity was further confirmed by western blot using 
anti-FLAG-tag monoclonal antibody (Additional file  1: 
Fig. S5c). These data further supported the ELISA results.
Thus, these results demonstrated that all three anti-
body fragments, which were secreted from S. cerevisiae, 
showed biological activity in binding to their correspond-
ing antigens.
Comparison of secretion capacity in different mutant 
strains
We initially expressed and tested all antibody fragments 
in the HA strain, which was derived from B184 exhibit-
ing high α-amylase secretion. To explore whether the 
improved secretion capacity of HA was generally appli-
cable to produce different pharmaceutical proteins, we 
Fig. 3 The binding activity of secreted antibody fragments in S. cerevisiae. a Schematic illustration of the sandwich ELISA format used here. b 
The binding activity of protein Nan to its corresponding antigen lysozyme from chicken egg white. c The binding activity of protein Pex to its 
corresponding antigen complement C5 from human serum. d The binding activity of protein Ran to its corresponding antigen human recombinant 
VEGF protein. Supernatants from HA.Nan, HA.Pex, HA.Ran and control HA.CPOTud strains were collected after 72 h of cultivation in SD-2xSCAA 
medium. Three antibody fragments were detected by ELISA signals (absorbance values are displayed as  OD450) using anti-6x-His-tag monoclonal 
antibody, HA.CPOTud as a negative control. Results are average values ± SD of biological triplicates (Nan) and duplicates (Pex and Ran)
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compared the production of the selected antibody frag-
ments in different host strains, LA (the low-secretion 
strain), MA (the medium-secretion strain) and HA (the 
high-secretion strain), respectively.
A phenotypic change of the host strain can be deter-
mined by the properties of expressed proteins, and the 
growth rate presents an important characteristic of 
the physiological state. We therefore analyzed the cel-
lular growth rate in a growth profiler prior to evaluat-
ing the secretory capacity. While the control strain LA 
containing an empty plasmid showed a typical diauxic 
growth behavior with a fermentative growth phase on 
glucose followed by a respiratory growth phase on etha-
nol, the protein expressing strains grew slower and did 
not display an obvious diauxic growth (Additional file 1: 
Fig. S6a). Moreover, all recombinant strains exhibited a 
longer lag phase and a decrease of the maximal specific 
growth rates compared to the corresponding strains con-
taining the empty plasmid (Additional file  1: Fig. S6b). 
The growth rate depended both on the expressed anti-
body fragment and the strain background. Strain HA 
always showed the highest growth rate, followed by MA 
and then the parental strain LA (Additional file  1: Fig. 
S6b). The results indicate that the increase of protein 
secretory capacity does not exert a negative effect on cell 
growth. On the contrary, the mutant strains grew faster, 
consistent with the previous study [29].
Furthermore, we compared the protein secretion level 
in three selected background strains. Western blot analy-
sis revealed that the amount of secreted Nan showed a 
significant increase in line with the evolution series. 
MA.Nan showed a 1.9-fold higher Nan titer, and HA.Nan 
could produce a 3.8-fold higher Nan titer compared to 
LA.Nan (Fig.  4a and b, Additional file  1: Fig. S7a). The 
amount of protein Ran presented a similar increasing 
tendency as Nan. MA.Ran, had a 1.8-fold higher produc-
tion of Ran, and HA.Ran could produce 10.1-fold more 
Ran than LA.Ran (Fig.  4  g and h, Additional file  1: Fig. 
S7c). On the other hand, protein Pex showed an oppo-
site trend. LA.Pex secreted a 3.5-fold higher amount 
compared with HA.Pex, while MA.Pex showed a 2.3-
fold higher titer than HA.Pex (Fig. 4d and e, Additional 
file  1: Fig. S7b). The results were further confirmed by 
ELISA (Fig. 4c, f and i). These data demonstrated that the 
expression and secretion of Nan and Ran were positively 
correlated with the strains’ secretory capacity (as deter-
mined by α-amylase) [28], while the protein Pex exhibited 
the highest secretion level in the parental strain LA.Pex. 
It is noteworthy that the abundance of the heavy chain of 
Ran under non-reducing condition and the small band of 
Pex were consistent with the secretory level of Ran and 
Pex, respectively (Additional file  1: Fig. S7b and c). The 
results imply that the previously evolved secretory strains 
are suitable candidates for production of pharmaceuticals 
with dedicated selection and optimization, but this strat-
egy may not be valid for all protein drugs.
Transcriptional response of the different protein 
expression strains
To explore the fundamental changes triggered by the 
expression of the different pharmaceutical proteins, 
RNA-seq analysis was performed. Here, we chose two 
proteins (Nan and Pex) in two host backgrounds (LA 
and HA) for comparison due to their opposite secretory 
trend. The production of Nan was higher in the HA.Nan 
strain in comparison to the LA.Nan strain. On the con-
trary, the production of Pex was lower in the HA.Pex 
strain than in the LA.Pex strain (Fig. 4, Additional file 1: 
Fig. S7).
For analysis of the differential gene expression, we 
performed pairwise comparisons between the mutant 
and parental strains for Nan and Pex production: Nan-
expressing strains (HA.Nan and LA.Nan) and Pex-
expressing strains (HA.Pex and LA.Pex). The global 
expression pattern was characterized using principal 
component analysis (PCA). PCA showed a strong group-
ing of biological replicates, indicating a high degree of 
reproducibility (Additional file 1: Fig. S8a). The HA and 
LA strains showed distinct gene expression profiles. The 
first component of the PCA accounted for 75% of the 
variance and showed significant differences between the 
different background strains. PC1 clearly separated HA 
strain and LA strain independent of the produced pro-
teins. For the LA strain, PC2 separated Pex and Nan, 
which was not the case for the HA strain. Differential 
gene expression analysis (p-adj and  log2 fold change) 
identified that in HA.Nan 2289 genes, about 34% of all 
genes of S. cerevisiae, were significantly (p-adj < 0.05) 
upregulated or downregulated compared with LA.Nan 
(Additional file 1: Fig. S8b) and 1960 genes in HA.Pex vs. 
LA.Pex (Additional file  1: Fig. S8c). We also performed 
gene expression analysis of LA.Nan vs. LA.Pex and 
HA.Nan vs. HA.Pex, but only few significantly changed 
genes were discovered. Therefore, to identify common 
expression changes of HA.Nan vs. LA.Nan and HA.Pex 
vs. LA.Pex, significantly differentially expressed genes 
(p-adj < 0.05,  log2 fold change < − 1 or > 1) were plotted in 
a Venn diagram (Additional file 1: Fig. S8d), and a total 
of 208 genes appeared in both HA.Nan vs. LA.Nan and 
HA.Pex vs. LA.Pex comparison (Additional file  2). To 
further investigate if the expression of the different pro-
teins affected the protein secretory pathway, the expres-
sion level of genes in every subsystem was evaluated 
(Fig.  5). No notable gene expression change was identi-
fied when comparing the respective strains expressing 
the two proteins, suggesting that the genes in the protein 
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secretory pathway were not influenced by the nature of 
the expressed protein. To further identify which genes 
might have important effects on antibody productiv-
ity, we first selected 2670 significantly changed genes 
in strain HA.Nan vs. LA.Nan (group I, p-adj < 0.05) or 
strain HA.Pex vs. LA.Pex (group II, p-adj < 0.05). Further, 
to identify differentially changed genes between group I 
and II, we selected genes based on the formula abs  (log2 
fold change I–log2 fold change II) > 1 and obtained 100 
genes. Of these, we selected ten directionally significantly 
changed genes for either deletion or overexpression 
according to the directional change in strain HA.Nan 
vs. LA.Nan (Additional file 1: Fig. S9a). And the genetic 
modifications were performed in strain LA.Pex. These 
ten genes were YDR344C, STL1, HXT3, TKL2, FRE4, 
KNS1, GIT1, AZR1, VMA1, and MIN7. Among them, 
manipulations of 5 genes, i.e. deletion of STL1, dele-
tion of TKL2, overexpression of GIT1, overexpression of 
Fig. 4 Comparison of protein secretion capacity in different mutant strains. Schematic illustration of antibody fragments (Nan (a), Pex (d) and Ran 
(g)). Supernatants from cultures of the antibody-expressing strains were collected after 72 h of cultivation and then processed. Western blot using 
anti-6x-His-tag antibody was performed under reducing (Nan (b) and Pex (e)) or nonreducing (Ran (h)) conditions. Data are expressed as average 
values ± SD of biological triplicates. The original images of the western blots are shown in Additional file 1: Fig. S7. For each protein, the secretion 
capacity in three yeast strains was evaluated (Nan (c), Pex (f) and Ran (i)). ELISA signals (absorbance values are displayed as  OD450) for different 
recombinants were obtained with anti-6x-His-tag monoclonal antibody. The HA strain carrying empty plasmid CPOTud was used as the negative 
control. Results are shown as average values ± SD of biological triplicates (Nan, CPOTud) and duplicates (Pex and Ran)
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AZR1, and overexpression of KNS1, showed a potential 
positive effect using an ELISA assay (Additional file  1: 
Fig. S9b). However, the standard deviations of some of 
the results were rather high. We then performed western 
blot to further confirm their effects. Only overexpression 
of KNS1 showed a distinct positive effect on Pex expres-
sion in strain LA (Additional file  1: Fig. S9c and S9d). 
KNS1 encodes a protein kinase involved in TOR signal-
ing and regulation of RNA polymerase III [45].
Gene Ontology (GO) term analysis is commonly 
used to identify enriched cellular responsive bio-
processes affected by different perturbations. First, we 
calculated the commonly changed bioprocesses repre-
senting consistent cellular responses during Nan and 
Pex expression (Fig.  6a). The up-regulated terms were 
related to protein synthesis and modification, cellular 
transport and certain metabolic processes, while the 
down-regulated terms were related to lipid and amino 
acid metabolic processes, and transport. As the HA and 
LA background strains exhibited different production 
capacities for the two proteins, with the aim to gain 
more insight in differently influenced biological pro-
cesses caused by these two proteins, we analyzed the 
inconsistent responses. From this analysis, we found 
that the significantly (p-adj < 0.01) up-regulated terms 
were concentrated on glycine and cysteine metabo-
lism, one-carbon and thiamine metabolism, and cell 
cycle in the HA.Nan strain compared to the LA.Nan 
strain, while the significantly down-regulated terms 
were focused on protein synthesis (Fig.  6a, Additional 
file 3). In strain HA.Pex vs. LA.Pex, the terms related to 
sporulation, and stress-associated responses were sig-
nificantly upregulated, while for down-regulated terms, 
MAPK cascade, ornithine and arginine metabolism, 
Fig. 5 Transcriptional changes of genes related to the protein secretory pathway. Transcriptome data are shown as fold changes in Nan and Pex 
expressing HA and LA strains. The left column represents the comparison between HA.Nan and LA.Nan, while the right is the comparison between 
HA.Pex and LA.Pex. Red and green boxes represent the corresponding value of the  log2 fold change (p-adj < 0.05) and white boxes represent 
p-adj ≥ 0.05. The same gene was classified into different subsystems based on the functional annotations
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and carbohydrate and polyphosphate metabolic pro-
cesses were enriched (Fig. 6a, Additional file 3).
To identify which biological processes exhibited signifi-
cant differences, we compared the same terms between 
HA.Nan vs. LA.Nan and HA.Pex vs. LA.Pex based on 
up- or down-regulation. To explore the key differences, 
we focused on the terms which showed significant 
changes (p-adj < 0.01) upon expression of one protein but 
not upon expression of the other protein (p-adj ≥ 0.01) 
(Fig. 6b and c). Concerning up-regulated terms, we found 
that the most significant differences for both proteins in 
different background strains were mainly related to the 
Fig. 6 GO term analysis for Nan and Pex expression in the mutant and parental strains. a Cellular responsive bioprocesses affected by different 
protein expression. Up and down represent up-regulation and down-regulation. Numbers represent the amount of genes in the up- and 
down-regulated terms. We compared the same terms between HA.Nan vs. LA.Nan and HA.Pex vs. LA.Pex based on up-regulation (b) or 
down-regulation (c). We focused on terms in part I and terms in part II that show significant differences for the expression of only one protein. 
The squares and dots on the plot represent the same terms. Dashed lines correspond to p-adj = 0.01. 0–2 indicates no significant differences 
(p-adj > 0.01) and > 2 indicates a significant difference (p-adj < 0.01). The terms A-L are marked on the plot and listed in the table (d)
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glycine catabolic process, one-carbon metabolic pro-
cess, glycine metabolic process and glycine decarboxyla-
tion via glycine cleavage system. The four processes were 
significantly upregulated (p-adj < 0.01) in the HA.Nan 
vs. LA.Nan while they were not significantly changed in 
HA.Pex vs. LA.Pex (Fig. 6b). Since both proteins contain 
a similar fraction of glycine residues, a higher glycine 
requirement for protein production would therefore not 
provide an explanation for this observation. To validate 
the potential effect of glycine metabolism on cellular pro-
duction of antibody fragments Nan and Pex, we changed 
the concentration of glycine in the SD-2xSCAA fermen-
tation medium. However, neither increase nor decrease 
of the glycine concentration in the medium revealed a 
clear trend in their effect on Nan and Pex production in 
strains LA and HA (Additional file 1: Fig. S10). Concern-
ing the down-regulated terms, we found that the cellular 
response to drugs, cellular iron ion homeostasis, per-
oxisome organization, and proteolysis were significantly 
downregulated (p-adj < 0.01) in strain HA vs. LA dur-
ing the expression of Nan, and ion transport and MAPK 
cascade were significantly downregulated (p-adj < 0.01) 
during the expression of Pex (Fig. 6c). These significantly 
downregulated terms in strain HA vs. LA were related 
to the stress response, while they were not significantly 
downregulated (p-adj < 0.01) in strain HA.Pex in com-
parison to LA.Pex. This indicated the expression of Pex 
might cause an increased cell stress in comparison with 
Nan.
Gene set enrichment analysis also revealed that, for the 
HA.Nan strain, pathways involved in amino acid metabo-
lism were significantly downregulated (p-adj < 0.05) in 
comparison to LA. Nan and therefore could result in a 
decreased protein synthesis (Additional file  1: Fig. S11a 
and b). This would relieve ER stress by reducing the load 
of newly synthesized proteins.
Discussion
During recent decades, the production of antibody frag-
ments has drawn increasing interest because they not 
only retain antigen binding properties but are also easier 
and less costly produced in microbial systems. Due to 
their small size, they can penetrate tissues and tumors 
more rapidly and more efficiently than the full size mAbs, 
which are used in tumor imaging, radiotherapy of can-
cers, and cardiovascular applications [6]. In our study, 
three antibody fragments with different configurations 
(such as disulfide bonds and molecular weights, Table 1) 
were successfully expressed in the high-level secretory 
platform strain HA.
In the process of antibody expression, the ratio of heavy 
and light chains is crucial for the final antibody produc-
tion and quality. This is also true for the expression of Fab 
fragments. Thus, an emerging challenge is to precisely 
control the relative expression level of both chains. 2A 
peptides, derived from viruses, have around 20 amino 
acids. The ribosomal skip occurs co-translationally 
between the last two amino acids, which results in equal 
amounts of the co-expressed proteins [46, 47]. Owing to 
highly efficient cleavage, 2A peptides have been used in 
various eukaryotic systems, including mammalian cell 
lines, plants and yeasts, and also successfully applied 
to control the performance of multi-step biosynthetic 
pathways [48, 49]. A study using human embryonic kid-
ney 293 cells showed that a full-length and functional 
monoclonal antibody was successfully expressed with a 
2A-mediated expression system [42]. The cleavage effi-
ciency of a 2A peptide may be affected by the nature of 
the protein expressed. Of the 2A peptides identified to 
date, four with varied cleavage efficiency have been com-
monly used in biomedical research: F2A from foot-and-
mouth disease virus, E2A from equine rhinitis A virus, 
P2A from porcine teschovirus-1 and T2A from Thosea 
asigna virus [50]. In this work, we used the 2A peptide 
from Thosea asigna virus. In addition to a band repre-
senting the assembled antibody fragment, we observed 
the single heavy chain and light chain bands under non-
reducing conditions, which might have resulted from 
incomplete assembly of heavy chain and light chain. 
The choice of the different signaling peptides for Ran-H 
and Ran-L may have resulted in differences in secretion 
efficiency of the two proteins although a previous study 
indicates that it should be similar for these two signal-
ing sequences [27]. In addition to the ratio of the two 
chains, the folding and assembly processes of mAbs and 
antibody fragments also depend on multiple disulfide 
bonds. Previous studies indicated that the formation of 
disulfide bonds between light chain and heavy chain is 
one of the main limitations of Fab quality and produc-
tion [51, 52]. In Pichia pastoris, owing to the inefficient 
formation of intermolecular disulfide bond, only about 
30% of Fab fragments were produced [44]. The require-
ment for formation of several disulfide bonds (Table  1) 
specifically the disulfide bond between  CH1 and  CL in 
Ran probably limited its efficient assembly and resulted 
in low production (Fig.  2c–e, Additional file  1: Fig. S1). 
An oxidizing environment is beneficial to the formation 
of disulfide bonds [53, 54]. For providing the oxidizing 
environment and therefore optimizing functional Ran 
production, it would be possible to examine the influence 
of culture conditions (i.e. dissolved oxygen, pH value or 
supplying oxidizing substances in the medium) or dimin-
ish the reductive pathways that accompany the secretion 
process. Such strategies might however also affect cell 
growth and/or viability. In addition, achieving success-
ful mAb assembly requires adopting more engineering 
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strategies, e.g. improving the assembling rate of the heavy 
chain and light chain in the ER and ensuring equal trans-
location effectiveness.
In our study, although three antibody fragments could 
be functionally expressed and secreted in yeast HA, an 
effective secretion strategy for one protein might not 
be generally applicable for improving production of 
another protein due to various factors that could affect 
the capacity of the yeast secretory machinery [27]. For 
example, the properties of the target protein, selection 
of genetic expression systems, capacity and efficiency of 
transcription and translation, protein folding and post-
translational modifications, and vesicle trafficking, may 
potentially represent bottlenecks that limit effective 
secretion of heterologous proteins [55]. We therefore 
evaluated the secretion capacity of these three antibody 
fragments in three different engineered strains. These 
strains have been assessed for the production of dif-
ferent enzymes but not for antibody fragments. Our 
results showed that the amount of secreted proteins dif-
ferentially correlated with the secretory capacity of the 
selected host strains. The secretion of Pex decreased with 
the increase of the secretory capacity, while the amounts 
of other two proteins were consistent with the increased 
secretory capacity [28]. The protein secretory pathway in 
eukaryal cells is a complex system and any change in the 
subsystems (i.e. translation and folding behavior) could 
lead to different levels of cell stress, cause different per-
turbations to protein secretion and hence result in dif-
ferent production levels. In this work, GO-term analysis 
was performed to examine different perturbations dur-
ing the expression of Nan and Pex in the low and high 
secretory host strains LA and HA. We found a significant 
difference for protein synthesis, protein modification, 
and amino acids metabolic process (Fig. 6a) which were 
probably related to protein secretion capacity. GO-term 
analysis also revealed that during the expression of Pex, 
the GO-terms related to stress responses were not sig-
nificantly downregulated in HA.Pex vs. LA.Pex, while 
HA.Nan vs. LA.Nan exhibited the opposite, coincid-
ing with the slight reduction of specific growth rate in 
the Pex expressing strain compared to the Nan and Ran 
expressing strains (Additional file 1: Fig. S6b). It is inter-
esting that we did not see these transcriptional changes 
in the original alpha-amylase strains, indicating an effect 
specifically caused by antibody fragment production [29, 
56]. To identify the effects of differentially changed genes 
on antibody fragment production, we tested ten signifi-
cantly changed genes and found that the overexpression 
of KNS1 had a positive effect on Pex expression in strain 
LA (Additional file  1: Fig. S9). As an important down-
stream element of TOR-dependent signaling, the kinase 
Kns1 is differentially expressed and hyperphosphorylated 
to regulate ribosome and tRNA synthesis in response 
to cellular stress or nutrient limitation [45], which fur-
ther indicates an important role of the stress response 
in antibody fragment production. An additional phe-
nomenon should be taken into account; only very small 
colonies appeared on the plates when the plasmid that 
encoded Pex was transferred into strains LA and MA. 
We suspect that the expression of Pex could compete for 
cellular resources and thus alter the intracellular metabo-
lism, which might cause a compromised cell growth. In 
addition, from GO-term analysis, we found that glycine 
metabolism related terms were significantly upregu-
lated in the strain HA.Nan vs. LA. Nan, but not in strain 
HA.Pex vs. LA.Pex. Upon changing the concentration of 
glycine in the fermentation medium, despite not finding 
a clear trend in the effect on the production of the two 
antibody fragments in strains LA and HA, we observed 
a varied production level of antibody fragments (Addi-
tional file 1: Fig. S10). All these data indicated that effi-
cient protein production also requires optimization of 
cellular metabolism to ensure sufficient supply of precur-
sors and energy for target protein production and allow 
the cells to quickly respond to different cellular pertur-
bations. We therefore conclude that both the stress and 
the allocation of cellular resources caused by Pex expres-
sion are presumably responsible for the low efficiency in 
secretion of Pex in the HA strain.
In summary, we demonstrated the secretion and bio-
logical specificity of three antibody fragments with dif-
ferent configurations (Table  1), evaluated the secretion 
capacity for these proteins in different mutant strains and 
explored the potential reasons for the differences in pro-
duction capacity by transcriptomics analysis. The results 
indicated that factors limiting the protein production 
not only reside in the secretory pathway but might also 
be related to the allocation of cellular resources. Future 
studies may focus on evaluating amino acid metabolism 
and activating stress responses to unfavorable environ-
mental changes for improving recombinant protein pro-
duction. It is important to move forward by exploring 
and rewiring these processes, as a foundation for future 
large-scale production of pharmaceutical proteins.
Methods
Media and culture conditions
Escherichia coli   was cultivated in LB medium supple-
mented with final concentrations of 100  mg/L ampicil-
lin or 50  mg/L kanamycin at 37  °C. Yeast strains were 
normally cultivated in YPD medium containing 10  g/L 
yeast extract (Merck Millipore), 20 g/L peptone (Difco), 
and 20  g/L glucose (VWR). Strains without plasmids 
were cultivated in YPE medium containing 10 g/L yeast 
extract, 20  g/L peptone, 10  g/L ethanol, and 0.5  g/L 
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glucose. Strains without the α-amylase plasmid were 
verified on starch agar plates, which contained 0.04  g/L 
glucose, 10 g/L starch, 6.9 g/L yeast nitrogen base with-
out amino acids (Formedium), and 20  g/L agar (Merck 
Millipore). The starch and ethanol agar plate consisted 
of 0.04  g/L glucose, 10  g/L starch, 6.9  g/L yeast nitro-
gen base without amino acids, 10 g/L ethanol, 790 mg/L 
complete supplement mixture (CSM) (Formedium), and 
20  g/L agar. Strains under amdSYM-selective condi-
tions were cultivated in SM-Ac medium containing 3 g/L 
 KH2PO4, 0.5 g/L  MgSO4·7H2O, 0.6 g/L acetamide, 6.6 g/L 
 K2SO4, 1 ml/L of a vitamin solution, 1 ml/L of a trace ele-
ment solution, and 20 g/L glucose [57]. The plates were 
prepared by adding 20 g/L agar to the medium. All yeast 
strains were cultured at 30 °C throughout this study.
Tube cultivations or shake flask batch fermentations 
for protein production were carried out in SD-2xSCAA 
medium containing 20 g/L glucose, 6.9 g/L yeast nitrogen 
base without amino acids, 190 mg/L Arg, 400 mg/L Asp, 
1,260 mg/L Gln, 130 mg/L Gly, 140 mg/L His, 290 mg/L 
Ile, 400  mg/L Leu, 440  mg/L Lys, 108  mg/L Met, 
200 mg/L Phe, 220 mg/L Thr, 40 mg/L Trp, 52 mg/L Tyr, 
380 mg/L Val, 1 g/L BSA, 5.4 g/L  Na2HPO4, and 8.56 g/L 
 NaH2PO4·H2O (pH 6.0). Single colonies were used to 
inoculate 14-mL tubes carrying 1.5 mL of liquid medium, 
which were subsequently incubated with 200-rpm agi-
tation for 24 h. Precultures were then used to inoculate 
100-mL unbaffled shake flasks carrying 20 mL of medium 
at an initial optical density at 600 nm  (OD600) of 0.05 and 
cultivated at 200 rpm for 72 h.
For recording cell growth, engineered strains were 
analysed with continuous orbital shaking using a growth 
profiler 960 (EnzyScreen). Precultures were used to inoc-
ulate a 96-well flat-bottom microplate (250  µl cultures) 
at an initial  OD600 of 0.05 and  OD600 values (referred to 
as  OD600 equivalents) were measured with an interval of 
30 min for 72 h.
Strains and plasmids
E. coli DH5α was used to construct and propagate the 
recombinant plasmids. All the S. cerevisiae strains were 
derived from the parental strain CEN.PK 530.1 C by UV 
mutagenesis [28] and plasmids are listed in Additional 
file 4: Table S1. All the primers were ordered from Euro-
fins Genomics and are listed in Additional file 4: Table S2. 
All the codon optimized heterologous genes were synthe-
sized from Genscript and are listed in Additional file 4: 
Table  S3. DNA sequencing services were provided by 
Eurofins Genomics.
The plasmid CPOTud as the backbone was digested by 
restriction enzymes KpnI and NheI. Gene Ran encoded 
two chains, part of the heavy chain with a 6xHis-tag 
(Ran-H) and the light chain with a FLAG-tag (Ran-L) at 
their respective C-termini. To co-express the two chains 
in one transcript, an 18-amino acid 2A self-processing 
peptide from Thosea asigna virus (EGRGSLLTCG-
DVEENPGP) was added at the C terminus of Ran-H 
[39]. To eliminate possible adverse effects caused by the 
remaining 2A residues, the construct also contained an 
additional Kex2 cleavage site (KR), which was located 
between the heavy chain and the 2A sequence. A GSG 
linker for higher 2A cleavage efficiency by creating 
greater flexibility was inserted between the additional 
Kex2 cleavage site and 2A peptide [40]. Ran-H and Ran-L 
were added with an alpha-factor leader (three glycosyla-
tion sites) and synthetic leader Yap3-TA57 (no glycosyla-
tion sites) at their N terminus [58]. The other three single 
peptides, Nan, Pex and Lyz (with 6xHis-tag, 6xHis-tag 
and FLAG-tag, respectively), were synthesized with an 
alpha-factor leader. All these assembled fragments were 
digested by KpnI and NheI, and then integrated into the 
backbone plasmid under the control of a strong TPI1 
promoter, resulting in pCP-Nan, pCP-Pex, pCP-Ran, and 
pCP-Lyz plasmids (Fig. 2a).
For obtaining the antibody fragment producing strains, 
the α-amylase expression plasmids were first eliminated 
from the mutant strains by a series of selective trans-
fers in YPE medium. In brief, one colony from each 
recombinant strain (AAC, MH34 and B184) was used to 
inoculate 1.5 mL of YPE medium. 10 µL of the culture 
were transferred into new YPE medium twice, and then 
streaked on a YPE plate. Loss of the α-amylase plasmid 
was confirmed by checking for the inability to use starch 
from starch agar plates indicated by a lack of growth and 
lack of a halo on the starch agar plate. Subsequently, the 
constructed plasmids pCP-Nan, pCP-Pex, pCP-Ran were 
used to transform the plasmid-depleted host strains LA, 
MA and HA, respectively.
For single gene deletions and promoter replacements, 
amdS was used as a marker for selection of transfor-
mants, which was amplified from plasmid pUG-amdSYM 
[55]. Gene deletion cassettes were assembled by the 
fusion of about 700 bp homologous sequences upstream 
to the target gene, amdS marker, and about 700  bp 
homologous sequences downstream to the target gene. 
Gene promoter replacement constructs were assembled 
by the fusion of about 700  bp homologous sequences 
upstream to the target gene, amdS marker, the strong 
TEF1 promoter, and the target gene. The cassettes were 
transformed into the host strain LA.Pex and selected on 
the SM-Ac plates. The lithium acetate method was used 
for transformations [59].
SDS‑PAGE and western blot
For SDS-PAGE and western blotting analysis, strains 
were grown in SD-2 × SCAA medium without BSA if not 
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specified. After cultivation, the supernatant was collected 
by centrifugation for 3000g, 4 min. For the visualization 
of the amount of secreted Pex, 1.8 mL of supernatant was 
concentrated 60-fold using the 10  K MW Pierce Con-
centrator PES (Thermo Scientific). For avoiding a too 
high amount of protein Nan, the supernatant was diluted 
10-fold using phosphate-buffered saline (PBS) buffer 
(8  g/L NaCl, 0.2  g/L KCl, 1.44  g/L  Na2HPO4, 0.24  g/L 
 KH2PO4, pH 7.4). For reducing SDS-PAGE, 10 µL of cell 
supernatants were mixed with 9 µL loading dye and 1 µL 
2-mercaptoethanol. For non-reducing SDS-PAGE, 10 µL 
of cell supernatants were mixed with 10 µL loading dye. 
In both cases, samples were heated at 98 °C for 5 min and 
then loaded on 4–20% tris-glycine pre-cast gels (Bio-Rad) 
and run for 1 h at 120 V in Tris/Glycine/SDS electropho-
resis buffer (Bio-Rad). Then the samples were either visu-
alized by staining with Coomassie Blue G-250 or further 
processed for western blot as described below.
Proteins in polyacrylamide gels were transferred to 
PVDF membranes using a Trans-Blot Turbo Transfer 
System (Bio-Rad). The membranes were washed with 
PBS and blocked for 1  h using 5% nonfat milk (w/v) in 
PBST (PBS containing 0.05% Tween-20). Membranes 
containing proteins were incubated with 1:2000-diluted 
anti-6x-His-tag monoclonal antibody (Thermo Scientific) 
or FLAG-tag monoclonal antibody (Thermo Scientific) 
in 1% milk (w/v)-PBST overnight at 4  °C and then with 
1:1000-diluted polyclonal goat anti-mouse immunoglob-
ulin antibody conjugated with horseradish peroxidase 
(HRP) (Dako) in 1% milk (w/v)-PBST for 1  h. Protein 
bands were visualized by exposure on a ChemiDoc XRS 
image analyzer (Bio-Rad) after the membranes had been 
treated with an enhanced chemiluminescent horseradish 
peroxidase substrate – SuperSignal West Dura Extended 
Duration Substrate (ThermoFisher Scientific). The inten-
sity of the bands was analyzed using Image Lab 6.0.1.
ELISA
An enzyme-linked immunosorbent assay (ELISA) was 
used to measure antigen-binding activity. MaxiSorp 96 
well ELISA plates were coated with 100 µL/well of 5 µg/
mL antigen in 0.05 M sodium carbonate buffer (1.515 g/L 
 Na2CO3, 3  g/L  NaHCO3, pH 9.6) overnight at 4  °C. All 
the antigens were obtained from Sigma-Aldrich, includ-
ing lysozyme from chicken egg white, Complement C5 
from human serum, as well as human recombinant VEGF 
protein. After removal of the coating solution, plates 
were washed twice with 200 µL PBST and blocked with 
blocking buffer (1% BSA in PBST) at room temperature 
for 1 h. Following four times of washing with 200 µL of 
PBST buffer, plates were incubated with protein samples 
for various processing conditions (The supernatant for 
protein Pex was 130 times concentrated, supernatant for 
protein Ran was not concentrated, and supernatant for 
protein Nan was 60 times diluted.) at successively var-
ied volume (0 µL to 80 µL) at room temperature for 1 h. 
After washing four times with the same buffer to remove 
unbound protein, 100 µL of anti-6x-His-tag monoclo-
nal antibody at various dilutions (1:500, 1:1000, 1:2000, 
1:3000, 1:4000, 1:5000) in blocking buffer was added to 
each well. Plates were washed and incubated with 100 µL 
of various dilution of polyclonal goat anti-mouse immu-
noglobulins/HRP antibody (1:500, 1:1000, 1:2000, 1:3000) 
in blocking buffer at room temperature for 1 h. To avoid 
forming red precipitate in the ELISA plate wells, we iden-
tified the optimal reaction condition, which was 1:5000 
dilution for the anti-6x-His-tag monoclonal antibody and 
1:3000 dilution for the polyclonal goat anti-mouse immu-
noglobulins/HRP antibody. For detection, 100 µL of the 
3, 3′, 5, 5′-tetramethylbenzidine (TMB) substrate was 
added and the activities of HRP were quantified by meas-
uring the absorbance at 450 nm using a plate reader- 
FLUOstar® Omega (BMG labtech).
Immunoprecipitation and pull‑down assay
Biological activity of the antibody fragment Nan was also 
demonstrated by monitoring the aggregation and disag-
gregation in the presence or absence of its target. Three 
yeast strains, containing three plasmids, which encoded 
Nan, its target Lyz and empty plasmid, were cultured in 
SD-2 × SCAA for 72 h. The supernatants were harvested 
by centrifugation at 3000g for 4  min. For clearly visual-
izing on SDS-PAGE gel, the supernatant containing the 
antigen Lyz was concentrated eight times. The pull-down 
assay was carried out using Dynabeads™ magnetic bead-
based technology (Invitrogen) according to the manu-
facturer’s protocol. Briefly, sample 1 was prepared in a 
volume of 700 µL 1 × Binding/Wash Buffer (2   ×  Bind-
ing/Wash Buffer: 100 mM sodium phosphate pH 8.0, 
600 mM NaCl, 0.02% Tween™ -20), and incubated with 
cobalt-based Dynabeads in the 1.5 mL-microcentrifuge 
tubes on a rotary shaker (Stuart) at 4 °C for 10 min. Then 
the tubes were put on a magnet for 2 min. After discard-
ing the supernatants, the beads were washed four times 
with 300 µL 1 × Wash Buffer by placing the tubes on a 
magnet for 2 min.
Similarly, sample 2 was prepared in a volume of 700 
µL 1 × Pull-down Buffer (2 × Pull-down Buffer: 6.5 mM 
Sodium-Phosphate pH 7.4, 140 mM NaCl, 0.02% Tween™ 
-20), and then added to above protein A-treated beads. 
Following incubation at 4  °C for 30  min on the rotary 
shaker, the beads were washed four times. To elute the 
protein, the beads were suspended in 100 µL of Elution 
Buffer (300 mM imidazole, 50 mM sodium phosphate 
pH 8.0, 300 mM NaCl, 0.01% Tween™ -20) and incubated 
on a Sample Mixer (Eppendorf ) for 10 min. The elution 
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fractions were analyzed by SDS-PAGE and transferred 
onto a PVDF membrane for verifying the presence of the 
FLAG-tag.
Transcriptome profiling
Cell samples for transcriptomic analysis were taken 
from biological triplicates at the early exponential phase 
 (OD600 ≈ 1). 10  OD600 of cells were added to ice-chilled 
15-mL falcon tubes containing approximately 10 mL 
ice and then immediately pelleted in a 4  °C pre-chilled 
centrifuge for 5  min at 2500  rpm. After centrifugation, 
supernatants were discarded, and cell pellets were snap 
frozen in liquid nitrogen and stored at −80 °C until fur-
ther analysis. RNA was extracted and purified using a 
Qiagen RNeasy Mini Kit (Qiagen) with a FastPrep-24 
homogenizer (MP Biomedicals) including DNA degrada-
tion according to manufacturer’s protocol. RNA integrity 
was assessed using a 2100 Bioanalyzer (Agilent Technol-
ogies). RNA concentration was determined by a Qubit 
RNA HS Assay Kit (Thermo Scientific) and cross-verified 
with a NanoDrop 2000 (Thermo Scientific). Libraries 
were prepared using an Illumina TruSeq Stranded mRNA 
Library Prep Kit (Illumina). Paired-end sequencing 
(2 × 150 bp) was carried out on a single lane on a HiSeq 
2500, according to the user’s manual. The Novo Nordisk 
Foundation Centre for Biosustainability (Technical Uni-
versity of Denmark) performed the RNA sequencing and 
library preparation. Read pairs were quality controlled 
from 24.7 to 29.8 million and mapped to the S. cerevisiae 
reference genome (Ensembl R64-1-1) using STAR. RNA-
seq data were processed using the nf-core RNAseq pipe-
line (SciLifeLab), available at https:// github. com/ nf- core/ 
rnaseq. Analysis of differential expression was performed 
using the DESeq2 package in the R programming lan-
guage. Reporter analysis on differential gene expression 
levels  (log2 fold change) and corresponding significance 
levels (p-adj, calculated by the Benjamini–Hochberg 
method) were used as input. Reporter analysis on GO 
terms was carried out by using the Platform for Inte-
grative Analysis of Omics (PIANO) R package with GO 
terms information from the SGD database (http:// www. 
yeast genome. org). The KEGG pathway functional catego-
ries enrichment analysis was performed by using online 
software David (Database for Annotation, Visualization, 
and Integrated Discovery), available at https:// david. ncifc 
rf. gov/.
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